| ²é¿´: 188 | »Ø¸´: 0 | ||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
Çó½Ì·Òë
|
| As Dll4 inhibitors are entering clinical cancer trials, this review aims to provide current perspectives on the function of the Dll4-Notch signaling axis during tumor angiogenesis and as a target for anti-angiogenic cancer therapy. |
» ²ÂÄãϲ»¶
0703»¯Ñ§µ÷¼Á 348·Ö
ÒѾÓÐ7È˻ظ´
³õÊÔ301£¬´úÂë085701»·¾³¹¤³Ì£¬±¾Ë¶Ò»Ö£¬ËÄÁù¼¶Òѹý£¬ÓжþÇøÒ»×÷£¬¹²·¢±í5ƪÂÛÎÄ
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸211£¬0703»¯Ñ§305·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ17È˻ظ´
266·Ö£¬Ò»Ö¾Ô¸µçÆø¹¤³Ì£¬±¾¿Æ²ÄÁÏ£¬Çó²ÄÁÏרҵµ÷¼Á
ÒѾÓÐ10È˻ظ´
²ÄÁÏ¿¼ÑÐÇóµ÷¼Á×Ü·Ö280
ÒѾÓÐ10È˻ظ´
312Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
327¿¼Ñе÷¼ÁÍÆ¼ö
ÒѾÓÐ4È˻ظ´
²ÄÁÏ¿ÆÑ§Ó빤³Ì320Çóµ÷¼Á£¬080500
ÒѾÓÐ6È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´















»Ø¸´´ËÂ¥